Security
Picard Medical, Inc. · PMI
PMINYSE_AMERICANCommon stockCurrentCIK 2030617Updated Oct 26, 2026
PMI price & chart
Loading TradingView…
AMEX:PMI on TradingView ↗About the company
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona - based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.
In the news
Kuehn Law Encourages Investors of Picard Medical, Inc. to Contact Law Firm ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Picard Medical, Inc. of Class Action Lawsuit and Upcoming Deadlines - PMI ↗
PMI Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Picard Medical, Inc. Securities Lawsuit -- The Gross Law Firm ↗
Recent filings
PRE 14A filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
S-3 filing
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 5.03, 9.01
Show 5 more recent filings
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 2.03, 3.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
NT 10-Q filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other Events
Items 3.01, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| AssetsUSD | 13,521,000Source | — | 9,167,000Source | 11,703,000Source | — | 11,220,000Source | — | 22,548,000Source | 12,106,000Source |
| Property, Plant and Equipment, NetUSD | 169,000Source | — | 162,000Source | 188,000Source | — | 184,000Source | — | 183,000Source | 227,000Source |
| GoodwillUSD | 615,000Source | — | 615,000Source | 615,000Source | — | 615,000Source | — | 615,000Source | 615,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 531,000Source | — | 465,000Source | 553,000Source | — | 487,000Source | — | 509,000Source | 596,000Source |
| Current assets: | |||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,813,000Source | — | 38,000Source | 410,000Source | — | 121,000Source | — | 7,451,000Source | 96,000Source |
| Inventory, NetUSD | 6,552,000Source | — | 5,970,000Source | 6,996,000Source | — | 7,445,000Source | — | 7,303,000Source | 8,115,000Source |
| Assets, CurrentUSD | 11,588,000Source | — | 7,592,000Source | 9,643,000Source | — | 9,509,000Source | — | 20,726,000Source | 9,791,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,060,000Source | — | 970,000Source | — | — | 1,347,000Source | — | 1,215,000Source | 955,000Source |
| Operating Lease, Right-of-Use AssetUSD | 474,000Source | — | 203,000Source | 550,000Source | — | 284,000Source | — | 363,000Source | 700,000Source |
| LIABILITIES AND EQUITY | |||||||||
| LiabilitiesUSD | 5,553,000Source | — | 7,451,000Source | 45,931,000Source | — | 12,668,000Source | — | 18,759,000Source | 35,842,000Source |
| Stockholders’ equity: | |||||||||
| Common Stock, Value, IssuedUSD | 7,000Source | — | 0Source | 1,000Source | — | 8,000Source | — | 7,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 80,283,000Source | — | 91,566,000Source | 7,370,000Source | — | 82,757,000Source | — | 80,397,000Source | 5,561,000Source |
| Retained Earnings (Accumulated Deficit)USD | -72,552,000Source | — | -90,119,000Source | -62,126,000Source | — | -84,459,000Source | — | -76,843,000Source | -49,841,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 230,000Source | — | 269,000Source | 262,000Source | — | 246,000Source | — | 228,000Source | 278,000Source |
| Stockholders' Equity Attributable to ParentUSD | 7,968,000Source | -35,398,000Source | 1,716,000Source | -54,493,000Source | -29,635,000Source | -1,448,000Source | -48,922,000Source | 3,789,000Source | -44,001,000Source |
| Liabilities and EquityUSD | 13,521,000Source | — | 9,167,000Source | 11,703,000Source | — | 11,220,000Source | — | 22,548,000Source | 12,106,000Source |
| Current liabilities: | |||||||||
| Liabilities, CurrentUSD | 5,373,000Source | — | 7,451,000Source | 45,636,000Source | — | 12,659,000Source | — | 18,695,000Source | 35,325,000Source |
| Operating Lease, Liability, CurrentUSD | 372,000Source | — | 235,000Source | 366,000Source | — | 329,000Source | — | 386,000Source | 371,000Source |
| Accounts Payable, CurrentUSD | 3,120,000Source | — | 3,323,000Source | 6,370,000Source | — | 2,711,000Source | — | 2,079,000Source | 5,293,000Source |
| Operating Lease, Liability, NoncurrentUSD | 136,000Source | — | 0Source | 234,000Source | — | 0Source | — | 34,000Source | 421,000Source |
| Additional Financial Items | |||||||||
| Dividends PayableUSD | 0Source | — | 0Source | — | — | 0Source | — | 0Source | 7,000,000Source |
| Accounts Receivable, after Allowance for Credit Loss, Current | — | — | — | —Source | — | — | — | — | — |
| Preferred Stock, Value, Issued | — | — | — | —Source | — | — | — | — | — |
| Accrued Liabilities, Current | — | — | — | —Source | — | — | — | — | — |
| Dividends Payable, Current | — | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 46,000Source | 42,000Source | 163,000Source | 226,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 165,000Source | 141,000Source | 754,000Source | 886,000Source |
| Changes in operating assets and liabilities: | ||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -27,000Source | -506,000Source | 120,000Source | -116,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 321,000Source | 246,000Source | -390,000Source | 1,330,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 632,000Source | 227,000Source | -3,211,000Source | 2,210,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,800,000Source | -2,241,000Source | -15,673,000Source | -11,874,000Source |
| Cash flows from investing activities: | ||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -26,000Source | 0Source | — | 0Source |
| Cash flows from financing activities: | ||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -7,522,000Source | 2,834,000Source | 27,078,000Source | 11,741,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -11,330,000Source | 592,000Source | 11,355,000Source | -148,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 6,000Source | 0Source | 259,000Source | 1,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 4,000Source | 0Source |
| Additional Financial Items | ||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 165,000Source | 141,000Source | 754,000Source | 886,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | 2,294,000Source | 0Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 22,000Source | 22,000Source | 87,000Source | — |
| DepreciationUSD | — | — | — | — | — | — | 25,000Source | 19,000Source | 76,000Source | 27,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | 0Source | -1,729,000Source | -7,040,000Source | -4,291,000Source |
| Dividends PayableUSD | — | — | 0Source | — | 0Source | — | 0Source | — | 0Source | 7,000,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | -4,535,000Source | -380,000Source | 0Source | -776,000Source | 0Source | -1,729,000Source | -7,040,000Source | -4,291,000Source |
| GoodwillUSD | — | — | 615,000Source | — | 615,000Source | 615,000Source | 615,000Source | — | 615,000Source | 615,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | — | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 7,000Source | 0Source | 0Source | 31,000Source | 35,000Source | -15,000Source |
| Inventory Write-downUSD | — | — | — | — | — | — | 180,000Source | 319,000Source | 423,000Source | 108,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -10,426,000Source | -6,206,000Source | -5,660,000Source | -6,724,000Source | -7,616,000Source | -5,561,000Source | -27,002,000Source | -21,055,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -10,426,000Source | -6,889,000Source | -5,660,000Source | -7,520,000Source | -7,616,000Source | -6,341,000Source | -27,002,000Source | -23,737,000Source |
| Nonoperating Income (Expense)USD | — | — | -6,939,000Source | -1,762,000Source | -1,024,000Source | -3,203,000Source | -3,105,000Source | -2,284,000Source | -13,710,000Source | -7,358,000Source |
| Operating ExpensesUSD | — | — | 3,357,000Source | 3,771,000Source | 5,245,000Source | 3,394,000Source | 4,786,000Source | 2,888,000Source | 13,053,000Source | 13,600,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 0Source | 0.5Source | 15,209,000Source | 0Source |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | — | — | — | — | — | —Source | — | — | — | — |
| Payments to Acquire Property, Plant, and Equipment | — | — | — | — | — | — | —Source | —Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | — | —Source | — | — | — | — |
| Dividends Payable, Current | — | — | — | — | — | —Source | — | — | — | — |
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | —Source | —Source | —Source | —Source | — | — |
| Other Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | — | — | — | — |
| Proceeds from Stock Options Exercised | — | — | — | — | — | — | —Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,187,000Source | 881,000Source | 2,954,000Source | 2,131,000Source | 1,150,000Source | 620,000Source | 4,940,000Source | 4,391,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Selling, General and Administrative ExpenseUSD | — | — | 2,406,000Source | 2,810,000Source | 3,871,000Source | 2,651,000Source | 2,891,000Source | 2,080,000Source | 10,004,000Source | 10,220,000Source |
| Operating Income (Loss)USD | — | — | -3,487,000Source | -4,444,000Source | -4,629,000Source | -3,521,000Source | -4,511,000Source | -3,246,000Source | -13,257,000Source | -13,712,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -10,426,000Source | -6,206,000Source | -5,653,000Source | -6,724,000Source | -7,616,000Source | -5,530,000Source | -26,967,000Source | -21,070,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 7,000Source | 0Source | 0Source | 31,000Source | 35,000Source | -15,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -10,426,000Source | -6,206,000Source | -5,660,000Source | -6,724,000Source | -7,616,000Source | -5,561,000Source | -27,002,000Source | -21,055,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.19Source | -0.87Source | -3.05Source | -42.39Source | -0.1Source | -0.8Source | -0.75Source | -2.99Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 54,452,140Source | 7,943,585Source | 1,855,813Source | 177,389Source | 74,437,715Source | 7,963,188Source | 36,233,084Source | 7,943,585Source |
| Additional Financial Items | ||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 22,000Source | 22,000Source | 87,000Source | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 35,000Source | -15,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | -4,535,000Source | -380,000Source | 0Source | -776,000Source | 0Source | -1,729,000Source | -7,040,000Source | -4,291,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | — | 0Source | 0Source |
| Gross ProfitUSD | — | — | -130,000Source | -673,000Source | 616,000Source | -127,000Source | 275,000Source | -358,000Source | -204,000Source | -112,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -27,002,000Source | -20,570,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | -2,404,000Source | -1,382,000Source | -89,000Source | -2,427,000Source | -5,000Source | -555,000Source | -5,393,000Source | -3,067,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -10,426,000Source | -6,889,000Source | -5,660,000Source | -7,520,000Source | -7,616,000Source | -6,341,000Source | -27,002,000Source | -23,737,000Source |
| Nonoperating Income (Expense)USD | — | — | -6,939,000Source | -1,762,000Source | -1,024,000Source | -3,203,000Source | -3,105,000Source | -2,284,000Source | -13,710,000Source | -7,358,000Source |
| Operating ExpensesUSD | — | — | 3,357,000Source | 3,771,000Source | 5,245,000Source | 3,394,000Source | 4,786,000Source | 2,888,000Source | 13,053,000Source | 13,600,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | 0Source | 683,000Source | 0Source | 796,000Source | 0Source | 780,000Source | 0Source | 2,682,000Source |
| Preferred Stock, Dividends Per Share, DeclaredUSD per share | — | — | — | — | — | — | 0Source | — | 0Source | — |
| Research and Development ExpenseUSD | — | — | 951,000Source | 961,000Source | 1,374,000Source | 743,000Source | 1,895,000Source | 808,000Source | 3,049,000Source | 3,380,000Source |
| Other Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | — | — | — | — |
| Common Stock, Dividends, Per Share, Declared | — | — | —Source | — | — | — | — | — | — | — |
| Depreciation, Depletion and Amortization, Nonproduction | — | — | — | — | — | —Source | — | — | — | — |
| Interest Expense | — | — | — | — | — | —Source | — | — | — | — |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic | — | — | — | — | — | —Source | — | — | — | — |
Offerings
Registration 333-299579
Registration 333-296060
Registration 333-295333
- Gross proceeds
- 5000000.0
- Net proceeds
- 4600000.0
- Deal price
- 0.3
- Shares
- 16666667
- Offering price
- $0.30
- Ticker
- PMI
Underwriters: WestPark Capital, Inc.
Registration 333-292666
Filing attachments
picardmedical_ex99-1.htm · 8-K · 2026-05-29
EX-99.1 2 picardmedical_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PICARD MEDICAL, INC. Issues Letter to Shareholders TUCSON, Ariz., May 29, 2026 - Picard Medical, Inc. (NYSE American: PMI) (the “Company” or “Picard Medical”), parent company of SynCardia Systems LLC, maker of the world’s first and only total artificial heart approved by both the U.S. FDA and Health Canada, today issued the following letter to shareholders: Dear Shareholders, Picard Medical, Inc. (NYSE American: PMI) (“Picard …
Read attachment ↗picardmedical_ex99-1.htm · 8-K · 2026-05-21
EX-99.1 2 picardmedical_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Picard Medical / SynCardia Reports First Quarter 2026 Financial Results - Gross profit turns positive; Company executes significant debt reduction - - Responds to NYSE American continued listing notice - TUCSON, Ariz., May 21, 2026 - Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC, (“SynCardia”) maker of the world’s first total artificial heart approved by …
Read attachment ↗picardmedical_ex4-1.htm · 8-K · 2026-05-11
EX-4.1 3 picardmedical_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 SERIES A COMMON STOCK PURCHASE WARRANT picard medical, Inc. Warrant Shares: _______________ Issue Date: May 6, 2026 ──────────────────────────────────────────────────────────────── THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set for…
Read attachment ↗picardmedical_ex4-2.htm · 8-K · 2026-05-11
EX-4.2 4 picardmedical_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 SERIES B COMMON STOCK PURCHASE WARRANT picard medical, Inc. Warrant Shares: _______________ Issue Date: May 6, 2026 ──────────────────────────────────────────────────────────────── THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set for…
Read attachment ↗picardmedical_ex4-3.htm · 8-K · 2026-05-11
EX-4.3 5 picardmedical_ex4-3.htm EXHIBIT 4.3 Exhibit 4.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT picard medical, Inc. Warrant Shares: _______________ Issue Date: May [●], 2026 ────────────────────────────────────────────────────────────────── THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●]. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set f…
Read attachment ↗picardmedical_ex4-1.htm · 8-K · 2026-05-05
EX-4.1 2 picardmedical_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THIS SECURITY AND ANY SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR (B) AN EXEMPTION FROM, OR IN A TRANSACTION …
Read attachment ↗